Integrating CT radiomics and transcriptomics: a biologically-informed machine learning model for predicting chemotherapy response in advanced laryngeal cancer

整合CT放射组学和转录组学:一种基于生物学信息的机器学习模型,用于预测晚期喉癌的化疗反应

阅读:1

Abstract

BACKGROUND: Predicting response to induction chemotherapy (IC) in advanced laryngeal cancer (LC) remains a clinical challenge. This study aimed to develop a non-invasive, interpretable model integrating CT radiomics and clinical features to predict chemotherapy outcomes. METHODS: We retrospectively analyzed 161 advanced LC patients treated with IC. From pre-treatment CT images, 1,321 radiomics features were extracted, and a radiomics score (Rad-score) was constructed using LASSO regression. Transcriptomic analysis explored the biological basis of Rad-score. Independent predictors were identified via multivariate logistic regression and used to build five machine learning models. Model performance was evaluated using AUC, accuracy, and specificity. SHAP analysis was applied to interpret the optimal model. RESULTS: Four robust radiomics features were selected to construct the Rad-score. The Rad-score demonstrated satisfactory discrimination with an Area Under the Curve (AUC) of 0.715 in the training set and 0.707 in the validation set. In multivariate analysis, the Rad-score (Odds Ratio [OR]=2.89, 95% CI: 1.29-6.48, P = 0.010), gap invasion and validation were identified as independent predictors of chemotherapy response. Among the machine learning models, the Random Forest model achieved the best performance, yielding an AUC of 0.914 in the training set, 0.856 in the validation set, and 0.810 in the external test set. Decision curve analysis confirmed the clinical utility of the model. SHAP analysis confirmed Rad-score and fat space invasion as core predictors, with synergistic effects. CONCLUSIONS: We developed a highly accurate and interpretable Random Forest model that integrates radiomics and clinical features to predict IC response in advanced LC. This tool enables precise risk stratification and personalized treatment decisions, sparing non-responders from ineffective therapy. Prospective studies are needed to validate its clinical utility.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。